Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Sage Therapeutic stock (SAGE)

Buy Sage Therapeutic stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Sage Therapeutic is a biotechnology business based in the US. Sage Therapeutic shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.91 – a decrease of 8.57% over the previous week. Sage Therapeutic employs 487 staff and has a trailing 12-month revenue of around $106.4 million.

Our top picks for where to buy Sage Therapeutic stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

Alternative pick for crypto trading

Go to site
  • $0 commission trading
  • Instant withdrawals with a 1.75% fee
  • Supports 250+ cryptocurrencies
  • High-yield account earns up to 4.65% APY
Terms apply. Cryptoassets are highly volatile. Your capital is at risk. Available in the US, CA, UK and AU

Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.

How to buy Sage Therapeutic stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – SAGE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Sage Therapeutic stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sage Therapeutic stock price (NASDAQ: SAGE)

Use our graph to track the performance of SAGE stocks over time.

Sage Therapeutic shares at a glance

Information last updated 2024-11-15.
Latest market close$4.91
52-week range$5.09 - $28.26
50-day moving average $7.05
200-day moving average $12.56
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-5.57

Is it a good time to buy Sage Therapeutic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sage Therapeutic price performance over time

Historical closes compared with the close of $4.78 from 2024-11-18

1 week (2024-11-13) -16.58%
1 month (2024-10-18) -36.86%
3 months (2024-08-20) -42.75%
6 months (2024-05-20) -57.25%
1 year (2023-11-20) -75.76%
2 years (2022-11-18) -86.71%
3 years (2021-11-19) 40.9
5 years (2019-11-20) 151.52

Is Sage Therapeutic stock undervalued or overvalued?

Valuing Sage Therapeutic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sage Therapeutic's PEG ratio

Sage Therapeutic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sage Therapeutic financials

Revenue TTM $106.4 million
Gross profit TTM $-319,290,000
Return on assets TTM -29.62%
Return on equity TTM -49.34%
Profit margin 0%
Book value $9.02
Market Capitalization $328.5 million

TTM: trailing 12 months

Sage Therapeutic share dividends

We're not expecting Sage Therapeutic to pay a dividend over the next 12 months.

Sage Therapeutic share price volatility

Over the last 12 months, Sage Therapeutic's shares have ranged in value from as little as $5.09 up to $28.26. A popular way to gauge a stock's volatility is its "beta".

SAGE.US volatility(beta: 0.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutic's is 0.924. This would suggest that Sage Therapeutic's shares are less volatile than average (for this exchange).

Sage Therapeutic overview

Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co. , Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc.

Frequently asked questions

What percentage of Sage Therapeutic is owned by insiders or institutions?
Currently 11.905% of Sage Therapeutic shares are held by insiders and 87.008% by institutions.
How many people work for Sage Therapeutic?
Latest data suggests 487 work at Sage Therapeutic.
When does the fiscal year end for Sage Therapeutic?
Sage Therapeutic's fiscal year ends in December.
Where is Sage Therapeutic based?
Sage Therapeutic's address is: 215 First Street, Cambridge, MA, United States, 02142
What is Sage Therapeutic's ISIN number?
Sage Therapeutic's international securities identification number is: US78667J1088
What is Sage Therapeutic's CUSIP number?
Sage Therapeutic's Committee on Uniform Securities Identification Procedures number is: 78667J108

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site